Next Article in Journal
Immunotherapies in Non-Hodgkin’s Lymphoma
Next Article in Special Issue
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
Previous Article in Journal
Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review
Previous Article in Special Issue
Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 14
10.3390/cancers13143624
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Reply published on 27 July 2021, see Cancers 2021, 13(15), 3763.
Comment of Cancers 2021, 13(5), 1176.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Comment

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176

by
Edouard Auclin
1,2,
Laura Mezquita
3,4,* and
Benjamin Besse
5
1
Department of Medical and Thoracic Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, 75015 Paris, France
2
Centre d’Investifation Clinique (Epidémiologie Clinique) INSERM 1418, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France
3
Medical Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
4
Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, The August Pi i Sunyer Biomedical Research Institute IDIBAPS, 08036 Barcelona, Spain
5
Department of Oncology, Institut Gustave Roussy, 94805 Villejuif, France
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(14), 3624; https://doi.org/10.3390/cancers13143624
Submission received: 26 May 2021 / Revised: 17 June 2021 / Accepted: 9 July 2021 / Published: 20 July 2021
(This article belongs to the Special Issue Cancer-Mediated Immunomodulation—Pathogenetic, Diagnostic and Therapeutic Aspects)
Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We read, with great interest, the recently published article by Hopkins et al. [...]

Share and Cite

MDPI and ACS Style

Auclin, E.; Mezquita, L.; Besse, B. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176. Cancers 2021, 13, 3624. https://doi.org/10.3390/cancers13143624

AMA Style

Auclin E, Mezquita L, Besse B. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176. Cancers. 2021; 13(14):3624. https://doi.org/10.3390/cancers13143624

Chicago/Turabian Style

Auclin, Edouard, Laura Mezquita, and Benjamin Besse. 2021. "Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176" Cancers 13, no. 14: 3624. https://doi.org/10.3390/cancers13143624

APA Style

Auclin, E., Mezquita, L., & Besse, B. (2021). Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176. Cancers, 13(14), 3624. https://doi.org/10.3390/cancers13143624

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop